Mean (SD) unless otherwise specified | All survey participants (N = 249) | High disease activity (n = 175) | Moderate/low disease activity or near REM (n = 74) | p valuea |
---|---|---|---|---|
Age, years | 51.7 (11.0) | 50.9 (10.6) | 53.7 (11.5) | 0.06 |
Females, n (%) | 229 (92.0) | 163 (93.1) | 66 (89.2) | 0.29 |
Ethnicity, white, n (%) | 225 (90.4) | 154 (88.0) | 71 (96.0) | 0.05 |
Time since diagnosis, years (SD) | 11.0 (9.5) | 10.8 (9.3) | 11.5 (10.1) | 0.62 |
Some college education or above, n (%) | 215 (86.4) | 150 (85.7) | 65 (87.8) | 0.66 |
Full-time employment, n (%) | 83 (33.3) | 58 (33.1) | 25 (33.8) | 0.92 |
Private insurance, n (%) | 154 (61.9) | 112 (64.0) | 42 (56.8) | 0.28 |
Current RA therapy, n (%) | ||||
Non-biologic DMARDs only | 72 (28.9) | 54 (30.9) | 18 (24.3) | 0.30 |
Biologic DMARDs | 150 (60.2) | 106 (60.6) | 44 (59.5) | 0.87 |
Steroid/NSAID/other/no treatmentb | 27 (10.8) | 15 (8.6) | 12 (16.2) | 0.08 |
Patient-reported outcomes, median (IQR) | ||||
RAPID3 (0–30 scale) | 15.0 (12.0–19.0) | 18.0 (15.0–20.0) | 8.0 (6.0–11.0) | < 0.0001 |
PROMIS-CAT measures (0–100 scale) | ||||
Pain interference | 63.3 (60.3–66.9) | 65.5 (62.7–67.8) | 58.0 (55.8–61.5) | < 0.0001 |
Fatigue | 63.0 (58.7–67.9) | 65.7 (62.3–69.4) | 56.7 (50.8–62.3) | < 0.0001 |
Physical function | 37.8 (34.0–40.8) | 35.5 (32.5–38.6) | 43.2 (39.5–45.8) | < 0.0001 |
Sleep disturbance | 59.2 (54.3–63.0) | 60.8 (55.8–64.9) | 55.6 (50.4–61.8) | < 0.0001 |